Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has issued a reminder letter to shareholders holding shares in physical mode, requesting them to furnish valid PAN, KYC details, bank account information, and nomination details. This action is in compliance with SEBI's Master Circular dated February 06, 2026. The company has completed dispatching these letters. Failure to provide the required information will result in the RTA, Cameo Corporate Services Limited, not processing any service requests or complaints. Furthermore, dividends will only be paid through electronic mode from April 1, 2024, for physical shares. Shareholders can access the necessary forms on the company's and RTA's websites.

Solara Active Pharma Sciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from Thursday, October 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter and half-year ending September 30, 2026. This measure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the Board Meeting to approve these financial results will be communicated later.

Solara Active Pharma Sciences Limited has received a Rectification Order from the Assistant Commissioner of Income Tax, Central Circle 3, Thane. This order rectifies an error in the tax computation related to a demand notice issued on March 17, 2026, for Assessment Year 2019-20. The company had applied for rectification under Section 154 of the Income Tax Act, 1961, stating the initial demand of ₹161.92 Crores was incorrectly calculated. The Rectification Order, issued under Section 154 read with Section 147, has now dropped the tax demand to Nil. The company confirms no financial impact or pending demand, and no aberrations or penalties were identified.

Solara Active Pharma Sciences Ltd has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, financial year reporting period, and stock exchange listings (BSE and NSE). It outlines the company's business activities, primarily focusing on the design and manufacture of Active Pharmaceutical Ingredients (APIs), which account for 100% of its turnover. The report also covers operational details, including 10 locations (6 manufacturing, 2 offices, 1 R&D center), markets served nationally and internationally, and export contribution (52% of turnover). Employee data for FY25-26 is provided, showing a total of 1032 employees and 2076 workers, with specific figures for male and female staff. The report confirms standalone reporting and does not have an assurance provider.

Solara Active Pharma Sciences Ltd has released its Annual Report for the financial year ended March 31, 2026, along with the notice for its Ninth Annual General Meeting (AGM). The AGM is scheduled for September 18, 2026, to be held virtually. The report highlights key financial and operational metrics for FY2025-26, including revenue of ₹1,375.14 Crores and EBITDA of ₹191.54 Crores. It also details the company's focus on cost optimization, R&D, and sustainability initiatives, including CSR investments of ₹0.76 Crores. The report is available on the company's website, and shareholders can participate via remote e-voting.

Solara Active Pharma Sciences Limited has announced the dispatch of the Notice for its Ninth Annual General Meeting (AGM). The AGM is scheduled to be held on Friday, September 18, 2026, at 10:30 AM IST, via Video Conference (VC) / Other Audio-Visual Means (OAVM). The meeting will include ordinary business such as adopting the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, and re-appointing Mr. Arun Kumar Pillai as a Non-Executive Director. Special business includes ratifying the remuneration for the Cost Auditors for the financial year ending March 31, 2027, set at ₹4,75,000 plus expenses and taxes. Shareholders can participate through remote e-voting from September 15 to September 17, 2026. The Annual Report for FY2025-26 is available on the company's website.

Solara Active Pharma Sciences Ltd announced the conversion of 2,79,582 partly paid-up Rights Equity Shares into fully paid-up equity shares. This action follows the receipt of pending call monies from shareholders who had not paid their First Call Money and/or Second and Final Call Money related to the company's rights issue. The conversion involves two tranches of shares with different paid-up amounts and ISINs. The company will undertake necessary corporate actions and seek listing approvals for these converted shares. This move aims to finalize the capital raised through the rights issue and consolidate the shareholding structure.

Solara Active Pharma Sciences Limited has revised the effective date for the appointment of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP). The appointment, initially set for August 10, 2026, has been postponed to August 17, 2026, due to personal reasons cited by Mr. Manocha. This update follows a previous intimation on July 23, 2026. Mr. Manocha brings over 33 years of experience in technology and life sciences transformation.

Solara Active Pharma Sciences Limited has announced the submission of its unaudited financial results for the quarter ended June 30, 2026. The results, which were approved by the Board of Directors at a meeting held on July 23, 2026, cover both standalone and consolidated financial statements. A limited review report from M/s. Deloitte Haskins & Sells, Chartered Accountants, has also been submitted. The financial results will be made available on the company's investor relations website.

Solara Active Pharma Sciences Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited. The report confirms that there has been no deviation or variation in the utilization of proceeds from its Rights Issue compared to the objects stated in the Letter of Offer. The Rights Issue, which involved equity shares, had a total issue size of ₹449.95 crore, with net proceeds of ₹446.95 crore being monitored by CRISIL. The company has declared that the utilization of funds aligns with the stated objectives, providing assurance to investors regarding the proper deployment of capital raised.